Ellis Investment Partners LLC Lowers Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Ellis Investment Partners LLC lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 5,813 shares of the specialty pharmaceutical company’s stock after selling 112 shares during the quarter. Ellis Investment Partners LLC’s holdings in Jazz Pharmaceuticals were worth $648,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its position in shares of Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the period. Finally, Gladius Capital Management LP bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth $33,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $1.50 during midday trading on Friday, hitting $109.55. The company had a trading volume of 505,816 shares, compared to its average volume of 541,919. The company has a fifty day simple moving average of $110.98 and a 200 day simple moving average of $109.57. The stock has a market cap of $6.76 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 1.41 and a beta of 0.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.48.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. As a group, analysts predict that Jazz Pharmaceuticals plc will post 16.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Royal Bank of Canada upped their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday. UBS Group cut their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a report on Tuesday, July 2nd. HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, Wells Fargo & Company dropped their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $173.43.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.